Clinical trials recruiting in Oceanside, California

Phase breakdown

Conditions recruiting in Oceanside, California

Recruiting trials in Oceanside, California

• A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
  NCT07277660 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
  NCT07459647 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07674654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT07115329 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female)
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  NCT05995964 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of NTX-1472 in Social Anxiety Disorder
  NCT07323784 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
  NCT06810505 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female)
• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
  NCT07573176 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
  NCT06389136 · Phase: Phase 3 · Ages: 18 Years to 63 Years · Sex: All (male and female)
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
  NCT06696755 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
  NCT05711394 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
  NCT07300969 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07645924 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
  NCT06223880 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT07196501 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
  NCT06917404 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• ALTO-100 in Bipolar Disorder With Depression (BD-D)
  NCT06656416 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• ALTO-207 in Adults With Treatment-resistant Depression (TRD)
  NCT07553637 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
  NCT07484217 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
  NCT07379827 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
  NCT07284979 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
  NCT07227818 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
  NCT07398417 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• MOTION Clinical Trial
  NCT06843980 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female)
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
  NCT07114874 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• Randomized Withdrawal Study in Patients With Schizophrenia
  NCT06961968 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
  NCT06229210 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female)
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
  NCT06701903 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
  NCT06480383 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female)
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  NCT06585410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
  NCT06890598 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
  NCT06846320 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  NCT05125302 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
  NCT07220460 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Oceanside, California?

41 recruiting trials have at least one study site in Oceanside, California.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.